An integrated strategy for Life Sciences in Europe

On Thursday, 4 June, AmCham EU’s Healthcare Committee hosted an online debate on its report 'Life Sciences in Europe – An integrated strategy for healthcare innovation (2019-2024)'. The panellists discussed the importance of building the resistance of health systems in Europe following the COVID-19 outbreak. A video recording of the event is available here

 

The event was opened by Susan Danger, CEO, AmCham EU. She spoke about the importance of the life sciences sector and its role in Europe’s economic recovery.

News
8 Jun 2020
Healthcare
An integrated strategy for Life Sciences in Europe

On Thursday, 4 June, AmCham EU’s Healthcare Committee hosted an online debate on its report 'Life Sciences in Europe – An integrated strategy for healthcare innovation (2019-2024)'. The panellists discussed the importance of building the resistance of health systems in Europe following the COVID-19 outbreak. A video recording of the event is available here

 

The event was opened by Susan Danger, CEO, AmCham EU. She spoke about the importance of the life sciences sector and its role in Europe’s economic recovery.

Before launching the panel into a discussion, the moderator, Philip Schwab (Abbvie), Issue lead on the life sciences for Europe report, AmCham EU asked the author of the report, Anthony Barron, Principal in the Life Sciences Practice, Charles River Associates to present his findings, taking into account the new challenges posed by the COVID-19 pandemic.

 

The panellists, Andrzej Rys, Director responsible for Health systems, medical products and innovation, DG SANTE, European Commission and Susana Solis Peres, MEP (Renew Europe, ES), European Parliament talked about the importance of reliable supply chains in Europe, investment in innovation and the digitalisation of healthcare.  

 

The speakers agreed that Europe cannot repeat the mistakes made during the previous economic crisis and that the well-being of citizens should remain at the centre of all policy making. The horizontal and integrated approach to life sciences technologies championed by the report was recognised as needed in Europe’s effort to sustainably improve its healthcare systems.

Related items

News
20 May 2026

Healthcare, competitiveness, innovation and simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Healthcare
Simplification
Read more
Read more about Healthcare, competitiveness, innovation and simplification
Position Paper
19 May 2026

Strengthening EU competitiveness through an adaptive MDR/IVDR framework

Healthcare
Read more
Read more about Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026

A global approach to strengthening Europe’s biotechnology ecosystem

Healthcare
Read more
Read more about A global approach to strengthening Europe’s biotechnology ecosystem